other material
confidence high
sentiment positive
materiality 0.85
Biomea Fusion reports 89% response rate and 1% median HbA1c reduction at 4 weeks for BMF-219 in T2DM Phase II
Biomea Fusion, Inc.
- Cohort 3 (100 mg BMF-219 without food, n=9) showed 89% response rate, median HbA1c reduction of -1.0% at day 28.
- 56% of Cohort 3 patients achieved >=1.0% HbA1c reduction; placebo (n=4) had median reduction of -0.1% to -0.15%.
- BMF-219 was well-tolerated; no discontinuations, serious AEs, or severe AEs across healthy volunteers and T2DM cohorts.
- Company plans to explore additional dosing periods >4 weeks and potential utility in type 1 diabetes.
- Dose escalation continues; negative food effect observed (3-fold exposure difference between fed and fasted cohorts).